Sector revisions Vertex Pharmaceuticals Incorporated

Stocks

Market Closed - Nasdaq 21:00:00 04/09/2026 BST			5-day change	1st Jan Change
546.12 ^USD	-2.12%		+0.82%	+20.46%

09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
09-01	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027	CI

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	VERTEX PHARMACEUTICALS INCORPORATED							26
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							22
	ABBVIE INC.							29
	ROCHE HOLDING AG							18
	NOVARTIS AG							21
	ASTRAZENECA PLC							22
	AMGEN INC.							29
	NOVO NORDISK A/S							23
	GILEAD SCIENCES, INC.							27
	PFIZER INC.							26
	BRISTOL-MYERS SQUIBB COMPANY							24
	SANOFI							23
	GSK PLC							20
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							16
	BAYER AG							18
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	TEVA PHARMACEUTICAL INDUSTRIES LIMITED							10
	HALEON PLC							17
	Average							22
	Weighted average by Cap.							24